Oncology nutrition market seen reaching $5.58 billion by 2035

Market Research Future projects the global oncology nutrition market will grow from $2.96 billion in 2025 to $5.58 billion by 2035, driven by rising cancer prevalence, stronger nutrition screening, and wider reimbursement. The report points to faster adoption of enteral, immunonutrition, and home-care products as hospitals and clinics build nutrition support into cancer treatment protocols.

Why it matters: - The oncology nutrition market is moving from optional support to a routine part of cancer care. - Market Research Future projects the global market will nearly double, reaching $5.58 billion by 2035 from $2.96 billion in 2025. - The forecast implies more spending on products that can help reduce treatment interruptions, support recovery, and improve patient tolerance to therapy.

What happened: - Market Research Future published a forecast for the global oncology nutrition market covering 2025 to 2035. - The report estimates a 6.55% compound annual growth rate over the forecast period. - The market base was estimated at $2.96 billion in 2025. - The report says the market is being driven by rising cancer prevalence, nutrition product innovation, and broader reimbursement pathways. - The report includes a sample request link: Request a free sample. - The report also includes the full study link: Read detailed insights.

The details: - Cancer incidence is projected to rise by about 2.1% annually through 2035, according to the report’s use of GLOBOCAN data. - Nutrition formulas are evolving toward immunonutrition and disease-specific products enriched with omega-3, high-leucine, arginine, nucleotides, and low-osmolality elemental lines. - Reimbursement support, including Medicare Part B coverage criteria for home enteral feeding and updated ESPEN clinical practice guidelines, is widening access. - Standard formula was the largest product segment in 2025, with a 48.3% share. - Disease-specific formula accounted for $0.63 billion. - Immunonutrition formula is the fastest-growing formula segment, at 8.37% CAGR. - Elemental and semi-elemental products held a 10.2% share in 2025. - Enteral nutrition dominated with a 70.3% share in 2025. - Parenteral nutrition is projected to grow at 7.12% CAGR. - Head and neck cancer was the largest cancer-type segment in 2025, with a 30.5% share. - Lung cancer is the fastest-growing indication, at 7.76% CAGR. - Stomach and gastrointestinal cancers represented $0.59 billion. - Breast cancer accounted for 12.6%. - Hospitals were the largest end-user segment, generating $1.84 billion in 2025. - Home care is the fastest-growing end-user segment, at 9.01% CAGR. - Specialty oncology clinics held a 13.6% share in 2025. - Hospital pharmacies remained the largest distribution channel. - Retail pharmacies supported outpatient and home-care continuity. - Online pharmacies are the fastest-growing distribution channel.

Between the lines: - The report suggests cancer nutrition is becoming more protocol-driven as hospitals link nutrition screening to treatment outcomes. - ESPEN audited European centers that implemented upstream nutrition screening and found a 21% reduction in unexpected treatment interruptions. - The market also appears shaped by purchasing power and care setting, with hospital contracting, reimbursement rules, and discharge pathways influencing adoption. - North America led the market in 2025 with 41.8% of global revenue, or about $1.24 billion. - Europe was the second-largest regional market at $0.78 billion. - Asia-Pacific is the fastest-growing region at 7.62% CAGR. - South America held about 5.6% of global share. - The Middle East and Africa market was valued at $0.13 billion in 2025. - Abbott Laboratories held an estimated 17% to 21% revenue share in the space. - Nestlé Health Science held about 15% to 19% of the market. - Danone, Fresenius Kabi, and Baxter International also ranked among the leading suppliers. - The top five suppliers held an estimated 61% to 66% of global revenue, indicating a moderately consolidated market.

What's next: - The report expects growth to continue through 2035 as more providers adopt oncology nutrition as part of standard cancer care. - Future opportunities include lower-cost products for emerging markets, precision nutrition, connected feeding devices, and value-based contracting tied to avoided readmissions and completed chemotherapy cycles. - Companies are likely to keep investing in disease-specific formulas, digital monitoring tools, and hospital distribution partnerships.

The bottom line: - Oncology nutrition is shifting from a niche support category to a larger, guideline-backed market tied directly to cancer outcomes and care delivery economics.